Amer Zeidan, Professor of Medicine, Chief of Hematologic Malignancies, Director of Heme Clinical Research at Yale University, shared a post on X:
”Looking forward to sharing in EHA2026 an updated analysis of MATHERHORN Ph3 trial of Roxadustat in lower risk MDSsm demonstrating efficacy and TI among high RBC transfusion burden patients and providing basis for a new planned Ph3 study to confirm the benefit in this population.”
Other Articles Featuring Amer Zeidan on OncoDaily.